Using synthetic biology to make new antibiotics
Research at Victoria University of Wellington could lead to a new generation of antibiotics, helping tackle the global
issue of ‘superbugs’ that are resistant to modern medicine.
Led by Mark Calcott, who has just completed his PhD study, under the supervision of Dr David Ackerley, an associate
professor in the School of Biological Science, the research is delivering new knowledge about how synthetic biology
might be used to counter bacteria that have become resistant to existing antibiotics.
The recently published study defines new ways that microbes, which are used to make some commonly used types of
antibiotics, can be reengineered to produce modified forms of the original molecules.
“Part of the problem is that people have historically been careless when using antibiotics, which has, one-by-one,
allowed bacteria to build resistance, thrive and multiply. We’re smarter now, but at a time when we’re running out of
options,” says Dr Ackerley.
“There is a serious and immediate need for new antibiotics—either we have to develop the next generation or find clever
and affordable ways of modifying the ones we currently have,” he says.
“The basis of our research is the idea that the microbial machinery (enzymes) that makes a particular antibiotic can be
rearranged, to make a different antibiotic that resistant bacteria won’t recognise. The new antibiotics will still fight
infection, and if we can use them in a more targeted way, bacteria won’t become resistant so easily.”
He says the ultimate goal of the study is to be able to produce high yields of new and affordable antibiotics that
‘superbugs’ don’t recognise and are not resistant to.
Results have been published by the American Society for Microbiology journal Applied and Environmental Microbiology,
viewable online here: http://bit.ly/1jpXM9U
The research is a core output of a grant Dr Ackerley has received from the Marsden Fund for a project called Cracking
the non-ribosomal code. Dr Ackerley is collaborating with Professor Iain Lamont from the Department of Biochemistry at
Otago University.
ends